Icon times
Decline in revenue with the rise in cost and shutdown of two manufacturing lines lead to degrowth of Gland Pharma | Q1 FY23 Result & Earning Call Highlights
Back
  • Home
  • Articles
  • Decline in revenue with the rise in cost and shutdown of two manufacturing lines lead to degrowth of Gland Pharma | Q1 FY23 Result & Earning Call Highlights

Decline in revenue with the rise in cost and shutdown of two manufacturing lines lead to degrowth of Gland Pharma | Q1 FY23 Result & Earning Call Highlights

Published on 22 July 2022 .Views 28 .Comments 0
Methodology Video
Share On
Please find attached for detailed analysis.
Attachments:
Tags:
#Q1 FY23 Result Analysis
#Earning Calls
private article suscription area icon

You like to know more. We like that!

Please subscribe Model Portfolio Plan to get access of all premium model portfolio articles Only at Rs. 11,999.00/Year.

Please login to view this free article.

This blog is available only for logged in users, please register and get access to view this article.

Recently Uploaded


premium Premium
free Free
View All
Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
16:10
Chat with InvestYadnya